Use the hyperlinks, where available to access additional clinical trial information.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody), in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
Eligible patients will be randomised into one of three Arms (A, B or C). In Arm A, patients will receive atezolizumab followed by tiragolumab. In Arm B, patients will receive atezolizumab followed by tiragolumab matching placebo. And, in Arm C, patients will receive matching placebos for both tiragolumab and atezolizumab.